ESTABLISHMENT LABS INC (ESTA)
Health Care · NASDAQ
A global medical technology company commercializing advanced silicone gel-filled breast implants with proprietary safety technologies aimed at improving aesthetic and reconstructive outcomes.
What ESTABLISHMENT LABS INC does
Establishment Labs is a global medical technology company focused on breast aesthetics and reconstruction through its Motiva Implants platform. The company designs, manufactures, and sells silicone gel-filled breast implants branded as Motiva, available in multiple product families including Round, Ergonomix Round, Anatomical, and newer Ergonomix2 variants. Motiva Implants incorporate first-of-its-kind safety features such as SmoothSilk surface technology, RFID tracking, BluSeal verification layers, and TrueMonobloc gel-shell configuration. The company distributes its products through exclusive distributors and a direct sales force across over 100 countries globally.
Themes: ["Breast aesthetics and reconstruction","Medical device safety and biocompatibility","Silicone implant technology","Patient outcome tracking and RFID identification"]
Fundamentals
- Price$88.77 as of 2026-07-09 close
- Market cap$2.6B as of 2026-07-10
- 1-year return+97.0% as of 2026-07-09 close
- Net margin-19.1% as of 2026-07-10
- Gross margin+70.1% as of 2026-07-10
- ROE-225.9% as of 2026-07-10
- Debt / equity17.58 as of 2026-07-10
- Revenue growth (YoY)+34.9% as of 2026-07-10
- Revenue CAGR (3y)+9.3% SEC XBRL
- Beta1.11 as of 2026-07-10
Key risks (from latest filing)
["Single-source raw material supplier for silicone; supply disruptions or price increases could adversely affect manufacturing and financial results.","Company is currently unprofitable (net margin -19.05%) and depends on commercial success of Motiva Implants; failure to maintain brand reputation or market demand could prevent profitability achievement.","Significant exposure to regulatory changes and compliance requirements in the highly regulated medical device industry; failure to comply or obtain necessary clearances could delay growth and impose penalties."]
Competitors & peers
- Allergan / AbbVie (breast implant portfolio)
- Mentor (Johnson & Johnson subsidiary)
- Sientra (SIEN)
- Natrelle breast implants (Allergan)
- Breast implants and aesthetic surgical devices
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.